About Novacta
Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.
In 2008 Novacta's newly appointed management took the strategic decision to divide the company into two distinct units that could focus on its key competencies.
The efficiency and flexibility of Novacta's novel business model and holding structure is specifically designed to encourage and facilitate partnering and service offerings.
Click here to see Novacta's story on Pharmatelevision
Novacta Therapeutics
Novacta Therapeutics is focused on bringing new and modern anti infective therapies to the market. The company is committed to bringing a new generation of agents with improved resistance profiles into development to combat the growing issue of hospital based infection. Using our lantibiotic platform a number of agents are being evaluated for C.difficile, Gram-positive and Gram-negative pathogens.
Go to: Novacta Therapeutics
Novacta Biosystems
Novacta Biosystems is a bespoke business which offers fee for service activities in the area of single step metabolite synthesis, biocatalysis and pathway engineering of bacteria and yeast. Its clients include blue chip pharmaceutical, biotechnology, agrochemical and biofuels companies.
Go to: Novacta Biosystems